Obesity-drug specialists Arena Pharmaceuticals (ARNA) and VIVUS (VVUS) have already launched their products in the United States, but both have struggled to get the green light in the European Union. While the two fight for market share in the U.S., Orexigen Therapeutics (NASDAQ: OREX), the third major player in this space, announced last week that it has submitted an application with the European Medicines Agency for the approval of its obesity medication Contrave. Orexigen has yet to get its drug approved by the FDA, but could it beat both Arena and VIVUS to the European market? Analysts David Williamson and Max Macaluso discuss this story in the following video.